Geode Capital Management’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.8M | Buy |
7,606,518
+631,252
| +9% | +$918K | ﹤0.01% | 2408 |
|
|
2026
Q1 | $9.21M | Sell |
6,975,266
-103,478
| -1% | -$185K | ﹤0.01% | 2429 |
|
|
2025
Q4 | $13.2M | Buy |
7,078,744
+172,089
| +2% | +$331K | ﹤0.01% | 2261 |
|
|
2025
Q3 | $8.84M | Buy |
6,906,655
+187,776
| +3% | +$254K | ﹤0.01% | 2480 |
|
|
2025
Q2 | $8.33M | Buy |
6,718,879
+401,637
| +6% | +$464K | ﹤0.01% | 2475 |
|
|
2025
Q1 | $7.46M | Buy |
6,317,242
+54,317
| +0.9% | +$83.3K | ﹤0.01% | 2460 |
|
|
2024
Q4 | $11.5M | Sell |
6,262,925
-64,981
| -1% | -$127K | ﹤0.01% | 2285 |
|
|
2024
Q3 | $10.8M | Buy |
6,327,906
+225,034
| +4% | +$370K | ﹤0.01% | 2332 |
|
|
2024
Q2 | $8.36M | Buy |
6,102,872
+460,093
| +8% | +$929K | ﹤0.01% | 2434 |
|
|
2024
Q1 | $21.2M | Buy |
5,642,779
+126,393
| +2% | +$740K | ﹤0.01% | 1887 |
|
|
2023
Q4 | $54.1M | Buy |
5,516,386
+412,150
| +8% | +$3.37M | 0.01% | 1297 |
|
|
2023
Q3 | $42.6M | Buy |
5,104,236
+182,428
| +4% | +$2.08M | 0.01% | 1330 |
|
|
2023
Q2 | $65.5M | Buy |
4,921,808
+190,699
| +4% | +$2.32M | 0.01% | 1060 |
|
|
2023
Q1 | $54.8M | Buy |
4,731,109
+561,499
| +13% | +$5.58M | 0.01% | 1123 |
|
|
2022
Q4 | $34.1M | Buy |
4,169,610
+140,672
| +3% | +$1.21M | ﹤0.01% | 1407 |
|
|
2022
Q3 | $23.4M | Sell |
4,028,938
-54,359
| -1% | -$312K | ﹤0.01% | 1619 |
|
|
2022
Q2 | $18M | Buy |
4,083,297
+240,733
| +6% | +$1.46M | ﹤0.01% | 1836 |
|
|
2022
Q1 | $35M | Buy |
3,842,564
+138,571
| +4% | +$1.6M | ﹤0.01% | 1503 |
|
|
2021
Q4 | $75.8M | Buy |
3,703,993
+218,252
| +6% | +$5.27M | 0.01% | 992 |
|
|
2021
Q3 | $89.1M | Sell |
3,485,741
-6,305
| -0.2% | -$187K | 0.01% | 873 |
|
|
2021
Q2 | $122M | Buy |
3,492,046
+237,209
| +7% | +$6.9M | 0.02% | 700 |
|
|
2021
Q1 | $108M | Buy |
3,254,837
+276,228
| +9% | +$9.67M | 0.02% | 720 |
|
|
2020
Q4 | $77.3M | Buy |
2,978,609
+470,245
| +19% | +$7.99M | 0.01% | 820 |
|
|
2020
Q3 | $24.8M | Buy |
2,508,364
+287,765
| +13% | +$1.66M | ﹤0.01% | 1376 |
|
|
2020
Q2 | $7.66M | Buy |
2,220,599
+70,238
| +3% | +$239K | ﹤0.01% | 2091 |
|
|
2020
Q1 | $6.58M | Buy |
2,150,361
+125,953
| +6% | +$516K | ﹤0.01% | 1989 |
|
|
2019
Q4 | $10.4M | Buy |
2,024,408
+117,342
| +6% | +$596K | ﹤0.01% | 1986 |
|
|
2019
Q3 | $9.84M | Sell |
1,907,066
-38,100
| -2% | -$213K | ﹤0.01% | 1942 |
|
|
2019
Q2 | $11.8M | Buy |
1,945,166
+194,655
| +11% | +$1.36M | ﹤0.01% | 1830 |
|
|
2019
Q1 | $12.7M | Buy |
1,750,511
+177,030
| +11% | +$1.28M | ﹤0.01% | 1739 |
|
|
2018
Q4 | $11.6M | Buy |
1,573,481
+156,404
| +11% | +$991K | ﹤0.01% | 1686 |
|
|
2018
Q3 | $7.67M | Buy |
1,417,077
+251,500
| +22% | +$1.08M | ﹤0.01% | 2098 |
|
|
2018
Q2 | $4.14M | Buy |
1,165,577
+153,641
| +15% | +$426K | ﹤0.01% | 2430 |
|
|
2018
Q1 | $2.07M | Buy |
1,011,936
+79,361
| +9% | +$206K | ﹤0.01% | 2733 |
|
|
2017
Q4 | $2.46M | Buy |
932,575
+57,374
| +7% | +$201K | ﹤0.01% | 2633 |
|
|
2017
Q3 | $4.59M | Buy |
875,201
+211,646
| +32% | +$910K | ﹤0.01% | 2253 |
|
|
2017
Q2 | $2.36M | Buy |
663,555
+7,352
| +1% | +$29.6K | ﹤0.01% | 2637 |
|
|
2017
Q1 | $3.39M | Buy |
656,203
+67,069
| +11% | +$328K | ﹤0.01% | 2351 |
|
|
2016
Q4 | $2.24M | Buy |
589,134
+14,177
| +2% | +$103K | ﹤0.01% | 2569 |
|
|
2016
Q3 | $5.15M | Buy |
574,957
+87,690
| +18% | +$733K | ﹤0.01% | 1954 |
|
|
2016
Q2 | $3.43M | Buy |
487,267
+14,167
| +3% | +$129K | ﹤0.01% | 2136 |
|
|
2016
Q1 | $4.02K | Buy |
473,100
+53,943
| +13% | +$531K | ﹤0.01% | 2007 |
|
|
2015
Q4 | $5.5M | Buy |
419,157
+11,597
| +3% | +$104K | ﹤0.01% | 1805 |
|
|
2015
Q3 | $1.49M | Buy |
407,560
+15,339
| +4% | +$75K | ﹤0.01% | 2631 |
|
|
2015
Q2 | $2.26M | Buy |
392,221
+27,124
| +7% | +$157K | ﹤0.01% | 2418 |
|
|
2015
Q1 | $2.13M | Buy |
365,097
+22,072
| +6% | +$152K | ﹤0.01% | 2401 |
|
|
2014
Q4 | $2.69M | Buy |
343,025
+40,120
| +13% | +$257K | ﹤0.01% | 2240 |
|
|
2014
Q3 | $1.49M | Buy |
302,905
+31,752
| +12% | +$166K | ﹤0.01% | 2551 |
|
|
2014
Q2 | $1.68M | Buy |
271,153
+6,716
| +3% | +$33.6K | ﹤0.01% | 2485 |
|
|
2014
Q1 | $1.41M | Buy |
264,437
+32,058
| +14% | +$203K | ﹤0.01% | 2561 |
|
|
2013
Q4 | $1.22M | Buy |
232,379
+13,258
| +6% | +$60.9K | ﹤0.01% | 2595 |
|
|
2013
Q3 | $1.21M | Buy |
219,121
+55,003
| +34% | +$191K | ﹤0.01% | 2490 |
|
|
2013
Q2 | $414K | Buy |
+164,118
| New | +$409K | ﹤0.01% | 2962 |
|
Other funds holding PACB
AIM
NAMA
Geode Capital Management's PACB Position: Q2 2026 in Review
Geode Capital Management increased its Pacific Biosciences (PACB) stake by 9% in Q2 2026, buying an estimated $918K and bringing the position to 7,606,518 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2408.
Geode Capital Management first reported a position in PACB in Q2 2013 and has held it in 53 quarters since. The position peaked at $122M in Q2 2021. 218 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Geode Capital Management held 7,606,518 shares of Pacific Biosciences worth $12.8M as of Q2 2026.
- Geode Capital Management bought 631,252 Pacific Biosciences shares in Q2 2026, an estimated $918K.
- Pacific Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2408 holding.
- Geode Capital Management first reported a position in Pacific Biosciences in Q2 2013 and has held it in 53 quarters since.
- Geode Capital Management's Pacific Biosciences position peaked at $122M in Q2 2021.
- 218 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.